Tamarly Intelligence
Company · EXEL (Nasdaq)

Exelixis, Inc.

Biological Products, (No Diagnostic Substances)

Key figures
Revenue, 2025
$2.32B
Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Institutional holders
756 at 30 Jun 2026 (701 the quarter before)
SEC number
939767
LEI
254900PJQB59O2O95R37

Source: SEC EDGAR filings and company facts, SEC Form 13F; checked 28 Oct 2026

About

Exelixis, Inc. is an American biotechnology company, headquartered in South San Francisco, founded in 1994.

Source: Wikidata

Latest filings
11 Sept 2026
8-K 8-K
31 Aug 2026
8-K 8-K
5 Aug 2026
10-Q 10-Q
5 Aug 2026
8-K 8-K
29 May 2026
8-K 8-K

Source: SEC EDGAR

With a free account

A free account opens 10 full pages a month and lets you follow this page: 12 quarters of figures, every filing and document, earnings call transcripts, holders and ownership changes, the Brain's cards and graph, exports to Excel.

Start freeSign in

Research from public records, not investment advice. Tamarly holds no investment positions. By reading these pages you accept the Terms of Use; figures can be late or wrong, so check the linked source before relying on one. Terms and policies.